Alloferon-1 Pharma Grade API is a synthetic tridecapeptide acetate supplied as a lyophilized powder or cake for formulation into tablet, capsule, granule, and injectable dosage forms. Two supply models are designated: ALF1-O for non-sterile oral solid processing and ALF1-I for low-endotoxin injectable manufacturing. The peptide chain contains 13 amino acid residues and no cysteine or methionine; disulfide scrambling is absent, and the principal chemical liabilities are deamidation, backbone hydrolysis, and histidine oxidation. The material is freely soluble in water at pH 5.0–6.5. Because no monograph is published in Ph. Eur., USP, or JP, release is controlled by a manufacturer specification aligned with ICH Q6A, and manufacturing follows ICH Q7. The API is intended for further pharmaceutical processing; it is not a sterile drug product and is not for direct patient administration.

Identification is confirmed by electrospray ionisation mass spectrometry, amino acid analysis, and reversed-phase HPLC retention time against a qualified reference standard. Solid-phase synthesis under Fmoc chemistry is used, and the peptide is isolated as an acetate salt by preparative HPLC and lyophilized. Residual host-cell protein and DNA testing are not applicable to the synthetic route. Batch-to-batch variance in water content is typically below 0.5% w/w when the lyophilization endpoint is confirmed by comparative pressure measurement.

Release Limits Differ Between Oral and Injectable Grades

Oral and injectable grades differ primarily in purity, water content, endotoxin burden, and bioburden. Table 1 presents representative release limits; each lot-specific certificate of analysis should be reviewed against the finished-product risk assessment. Analytical methods are validated under ICH Q2(R1) for specificity, linearity, accuracy, precision, and range. Residual trifluoroacetic acid, where used in cleavage, is controlled below 0.10% w/w after acetate exchange. The acetate counterion is controlled at 5.0–12.0% to maintain solubility and pH on reconstitution. The impurity profile includes deletion sequences and truncated peptides typical of solid-phase peptide synthesis; each individual impurity above 0.10% is reported, and total related substances are limited to ≤5.0% for oral grade and ≤2.0% for injectable grade.

Residual solvents are controlled according to ICH Q3C. For the injectable grade, acetonitrile is limited to ≤410 ppm because of its use in preparative chromatography; for the oral grade, only Class 3 solvents are normally detected. Elemental impurities are assessed under ICH Q3D Option 1. Because the intended daily dose is low, the oral permitted daily exposure for lead of 5.0 µg/day and the parenteral permitted daily exposure for cadmium of 2.0 µg/day typically translate into API limits that are not restrictive for standard manufacturing. Peptide content is expressed on an anhydrous, acetate-free basis; water content is measured by Karl Fischer titration according to USP <921> Method Ia. Bacterial endotoxins are measured by limulus amebocyte lysate testing under USP <85>, and microbial enumeration follows USP <61>.

For low-dose tablet and capsule formulations, the critical processing challenge is blend uniformity rather than API flow. Active contents commonly fall between 0.1 mg and 10.0 mg per unit; the API is therefore dispersed by geometric dilution into mannitol or low-reducing-sugar lactose monohydrate. Blend uniformity testing should follow USP <905> with an acceptance value of ≤15.0 for the final blend. Particle size is controlled with d90 ≤ 75 µm; coarser material improves flow but increases segregation risk in low-dose direct compression. Loss-on-drying of the final blend is maintained at ≤2.5% before compression. A rotary tablet press operating at 8–15 kN compression force and 20–40 rpm is typically suitable when the lubricant is sodium stearyl fumarate at 0.5% w/w; magnesium stearate levels above 1.0% w/w can reduce hardness and extend disintegration time. Capsule filling requires in-process potency checks during the first 10 min and after each hopper refill to detect segregation. For granule production, fluidized-bed top spray with a 5% w/w aqueous binder solution, product temperature below 35°C, and spray rate calibrated to avoid over-wetting is preferred; final granule moisture is dried to ≤2.0% before filling into sachets or bottles. Excipient compatibility studies should include binary blends exposed to 40°C/75% RH for 4 weeks; aldehyde-containing lactose grades should be avoided because they can form Schiff bases with the amino terminus and histidine side chains. Tablet hardness is controlled between 4 kp and 8 kp for immediate-release formulations; friability is maintained at ≤1.0% after 100 rotations under USP <1216>. Disintegration testing under USP <701> is conducted in 900 mL of water or 0.1 N hydrochloric acid at 37±2°C.

Which Process Limits Apply to Lyophilized Injectable Solutions?

For the injectable grade, solution preparation occurs with Water for Injection at 5–15°C. The peptide is dissolved under gentle agitation; high-shear mixing above 1,000 rpm is avoided because it foams and increases surface adsorption to stainless steel and glass. Target solution concentrations are commonly 0.05–1.0 mg/mL before lyophilization; concentrations above 1.0 mg/mL may require pH adjustment to 5.0–5.5 to prevent precipitation of the acetate salt. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide; phosphate buffers at pH above 7.0 are not used due to accelerated deamidation. Sterilization is performed by aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane; nylon and mixed-cellulose ester filters are not recommended because peptide adsorption can reduce recovered potency by more than 10%. Terminal autoclaving at 121°C is not the primary sterilization route because thermal exposure above 60°C promotes backbone hydrolysis. For lyophilization, mannitol or trehalose at 2–5% w/v serves as a bulking and cryoprotective agent. Freeze-drying cycles with freezing to −40°C, annealing at −10°C for 2 h, primary drying at −20°C, and chamber pressure of 80–120 mTorr produce a mechanically stable cake. Collapse temperature should be confirmed by freeze-drying microscopy for each formulation; published data for this specific configuration is limited. Container closure systems should use Type I borosilicate glass vials and butyl rubber stoppers; silicone oil levels should be minimized because the peptide can adsorb to silicone interfaces. After reconstitution, the solution is visually inspected for particulate matter, and subvisible particles are controlled under USP <788>. The final injectable drug product must meet sterility testing under USP <71>.

When Direct Compression Is Preferred Over Wet Granulation

Direct compression is preferred when the active dose is low, the API particle size distribution is consistent, and the formulation contains ≤30% w/w of hygroscopic excipients. Wet granulation increases moisture contact time and can accelerate deamidation of the glutamine residue; if aqueous granulation is unavoidable, the binder solution is maintained at pH 5.0–6.5 and drying is performed at ≤40°C. A 10 L high-shear granulator can be used for development batches, but the wet-mass torque is equipment-specific; over-wetting is typically indicated by an impeller torque increase of more than 20 N·m when granulating liquid exceeds 12–15% w/w. Dry granulation by slugging or roller compaction is the alternative when direct compression fails due to segregation; roll force is selected to achieve a ribbon solid fraction of 0.65–0.75, and milled granules are screened through a 500 µm mesh. The selection between direct compression and dry granulation should be supported by blend uniformity data under USP <905> and by disintegration testing under USP <701>. On a production scale, a bin blender with an intensifier bar is preferred; blending at 10 rpm for 20 min is a common starting point, but blend time must be optimized by sampling at 10 locations.

Forced Degradation Pathways and Storage Constraints

Forced degradation of the acetate salt shows pH-dependent degradation. Deamidation of the glutamine residue and hydrolysis of the peptide backbone are the primary pathways above pH 6.5; acid-catalyzed cleavage increases below pH 3.0. Oxidation of histidine residues is observed after exposure to 0.1% v/v hydrogen peroxide; the absence of methionine and cysteine does not eliminate oxidative risk. The lyophilized powder is stored in amber glass vials with desiccant at −20±5°C for long-term use; storage at 2–8°C is acceptable for up to 24 months for the oral grade if water content remains below 7.0%. Once dissolved, the solution should be used within 8 h at 2–8°C or 4 h at room temperature unless formulation-specific stability data are available. The API is incompatible with strong bases, hypochlorite solutions, and metal ions such as Fe³⁺ and Cu²⁺; these ions catalyze peptide oxidation and should be excluded from manufacturing water by chelation or by use of Water for Injection. Avoid combination with amine-based buffering agents that raise pH above 7.0, including tromethamine; such combinations can cause rapid degradation and should not be considered without a forced degradation study. Light exposure studies under ICH Q1B are required for injectable formulations; histidine-containing peptides can form photoproducts. The oral grade should be protected from light and stored in opaque packaging. Long-term, accelerated, and intermediate stability protocols should follow ICH Q1A(R2); bracketing or matrixing may be justified for multiple strengths.

Why Alloferon-1 Differs From Thymosin α1 and Thymopentin

Compared with Thymosin α1 and Thymopentin, Alloferon-1 occupies a distinct position in short immunomodulatory peptide APIs. Its chain length of 13 residues and nominal molecular mass of approximately 1.27 kDa place it between the 5-residue Thymopentin and the 28-residue Thymosin α1. Because Alloferon-1 contains no sulfur-containing amino acids, its solid-state oxidation profile differs from peptides that include methionine. However, the presence of multiple histidine residues increases the need for strict control of pH and metal ion contamination. The acetate salt is selected over trifluoroacetate to reduce residual fluorine and to improve compatibility with injectable buffers; this is a difference from research-grade peptide supplies that are commonly lyophilized from trifluoroacetic acid. Pharmacopeial monographs are not currently available for Alloferon-1; finished-product developers should therefore justify specifications through ICH Q6A, analytical method validation under ICH Q2(R1), and stability protocols under ICH Q1A(R2). Table 2 summarizes the comparative profile.

Published clinical or pharmacokinetic data for Alloferon-1 oral absorption in humans is limited; selection of an oral dosage form should be supported by Caco-2 permeability, solubility in biorelevant media, and, if possible, a phase I bioavailability pilot. The injectable route has a more established peptide-handling precedent, but the specific immunomodulatory efficacy, dosing frequency, and safety margin for Alloferon-1 must be confirmed in the relevant regulatory jurisdiction. Finished products must comply with 21 CFR 210/211 for manufacturing practice, USP <1> for injectable dosage forms where applicable, and regional requirements for synthetic peptide active substances.